DNMT3A Gene Methylation Analysis for AML Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining predisposition to hematopoietic malignant myeloid diseases like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) lack effective predictive biomarkers and understanding of epigenetic control mechanisms, particularly for DNMT3A and DNMT3B genes, which are crucial in disease development and progression.
Innovation Solution
A method involving the determination of methylation levels in specific regions of the DNMT3A gene using nucleic acid samples from individuals, comparing these levels to reference methylation levels in healthy individuals to assess predisposition and evaluating therapy response by measuring changes in methylation levels post-treatment with DNA-methyltransferase inhibitors or anthracycline antibiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If DNA-methylation analysis of DNMT3A gene is performed to determine predisposition to hematopoietic malignant myeloid diseases, then diagnostic accuracy and predictive capability are improved, but test complexity and cost increase
Solution Approach 1:
The patent segments the DNMT3A gene into specific regions containing CpG-dinucleotides for methylation analysis, focusing on particular exons and regulatory regions rather than analyzing the entire gene. This segmentation maintains diagnostic accuracy while reducing test complexity by targeting only the most informative regions.
Solution Approach 2:
The patent applies local quality by identifying and analyzing specific CpG-dinucleotide sites within the DNMT3A gene that have differential methylation patterns in diseased versus healthy individuals. Rather than uniform analysis across the entire gene, the method focuses on locally significant regions where methylation changes are most predictive of disease predisposition.
2Reliability
If methylation level determination is performed on multiple CpG-dinucleotides in DNMT3A gene, then predictive reliability is improved, but measurement time and resource consumption increase
Solution Approach 1:
The patent extracts and analyzes only the most informative CpG-dinucleotides from the DNMT3A gene that show significant methylation differences between healthy and diseased states. By selecting a limited subset of high-value targets rather than analyzing all possible CpG sites, the method maintains predictive reliability while significantly reducing measurement time and resource requirements.
Solution Approach 2:
The patent employs preliminary action by pre-identifying and selecting specific CpG-dinucleotide sites in the DNMT3A gene that are most strongly associated with hematopoietic malignant myeloid diseases. This pre-selection of target sites based on prior knowledge of disease-associated methylation patterns enables rapid and reliable testing without requiring comprehensive analysis of all potential sites.
3Loss of information
If comprehensive epigenetic analysis of DNMT3A and DNMT3B genes is conducted, then understanding of disease mechanisms is improved, but analytical complexity and cost increase
Solution Approach 1:
The patent applies local quality by focusing epigenetic analysis on specific functional regions of the DNMT3A and DNMT3B genes, particularly promoter regions and exons containing CpG-dinucleotides that are most relevant to gene regulation and disease pathogenesis. This targeted approach provides sufficient mechanistic insight while avoiding the complexity of genome-wide epigenetic analysis.
Solution Approach 2:
The patent extracts key epigenetic information by analyzing only the most relevant methylation sites in DNMT3A and DNMT3B genes that directly relate to disease mechanisms. By selecting specific CpG sites in regulatory regions and comparing their methylation status, the method captures essential mechanistic insights without requiring comprehensive analysis of all genomic regions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for accurate assessment of an individual's risk of developing AML or MDS and evaluates the effectiveness of therapies by quantifying methylation changes, potentially guiding therapeutic decisions and risk stratification.
Implementation Method 1
DNA-methylation (DNAm) of CpG dinucleotides is a key epigenetic process
Data Source
Figure 1a~1c
Figure 2a~2g
Figure 3a~3c
AI summary
The invention concerns a method for determining a human individual's predisposition to contract a hematopoietic malignant myeloid disease, wherein a methylation level of at least one specific region of a nucleic acid comprising at least one CpG-dinucleotide is determined, wherein the specific region comprises at least one gene selected from the group consisting of DNA-methyltransferases, and wherein the determined methylation level is compared with at least one reference methylation level of the specific region, wherein the risk of the human individual to contract the myeloid disease is increased if the determined methylation level is altered in respect of the reference methylation level. The invention further concerns the use of said nucleic acid molecule and a kit for determining a human individual's predisposition to contract a malignant disease according to said method.